Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

AstraZeneca sells Ohio manufacturing site to National Resilience

By Brian Buntz | December 1, 2022

Resilience/AstraZenecaAstraZeneca (LON:AZN) has sold its site in West Chester, Ohio, to National Resilience, a San Diego–headquartered biomanufacturing company.

Resilience has agreed to maintain the site’s operations and assets while retaining its employees, including executives. The company will also continue investing in the site’s workforce and facility.

Privately-held National Resilience also has separately announced that it had reached a long-term biomanufacturing partnership supporting AstraZeneca’s portfolio.

That deal will give AstraZeneca access to Resilience’s end-to-end manufacturing services. In addition, Resilience agreed to purchase the West Chester facility and to manufacture several AstraZeneca drugs at the site as part of a multi-year supply agreement.

Resilience believes the West Cheser site will become its “global center of excellence for commercial drug product manufacturing,” noted Rahul Singhvi, Resilience CEO, in a news release. “This partnership is an exciting step toward our mission of broadening patient access to complex medicines and protecting domestic biopharmaceutical supply chains.”

West Chester, Ohio

AstraZeneca has agreed to sell its site in West Chester, Ohio to National Resilience.

“As part of our long-term strategy to ensure our global supply network remains fit for the future, we are continuously optimizing our manufacturing footprint to meet the evolving needs of our pipeline and portfolio,” said Andrew Wirths, senior vice president, Americas Supply Region at AstraZeneca, in a news release. “The transfer of our West Chester site to Resilience will enable the continued supply of AstraZeneca medicines to patients, as well as the continued employment for more than 500 people working at the West Chester site. I’m encouraged by Resilience’s plans to transform the site into their drug product center of excellence.”

The site is a 580,000 ft2 facility with end-to-end drug product manufacturing equipment. Additionally, it is capable of aseptic filling, inspection, packaging, labeling and cold-chain operations.

The site is equipped to produce vials, cartridges, pre-filled syringes and autoinjectors. It also has a virtual reality training center.

The two companies estimate that the transaction will be finalized in early 2023, subject to customary regulatory approvals.

Upon closing, National Resilience will acquire the West Chester site’s operations and physical assets, retain the site’s leadership and employees, and continue to invest in the workforce and facility.

In June, National Resilience raised $625 million in a Series D financing. The company also had raised $600 million in Series C financing in August 2021.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE